Tivozanib: Additional Phase II data

Additional data from a placebo-controlled Phase II trial in 272 patients naïve to VEGF therapy showed that once-daily oral tivozanib led to a median

Read the full 244 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE